Thomas Bicsak, PhD
Thomas Bicsak joined Elcelyx as Vice President, Regulatory Affairs and Quality Assurance in 2014 and assumed the position of Senior Vice President in 2016. He was formerly Vice President, Regulatory Affairs at Orexigen Therapeutics, where he served in a leadership capacity in support of the US and EU approvals for Contrave® and Mysimba™ (naltrexone/bupropion for the treatment of obesity). Prior to Orexigen, Dr. Bicsak was at Amylin Pharmaceuticals, where he held positions of increasing responsibility in Medical Writing and Regulatory Affairs. At Amylin, he was US Regulatory Lead for the Bydureon® (exenatide extended-release for the treatment of type 2 diabetes) development program and NDA, and was a key contributor supporting the US approvals for Byetta® and Symlin®. Dr. Bicsak also worked at Dura Pharmaceuticals and Johnson and Johnson, contributing to development programs and several US and EU product approvals over a range of therapeutic areas including hematology, immune response, oncology, respiratory medicine, and wound healing. Dr. Bicsak has authored or co authored over 20 original publications.
Dr. Bicsak graduated from Rutgers University with a BA (with honors) in Biochemistry and received MS and PhD degrees in Chemistry from the University of California, San Diego. He also completed postdoctoral studies in Reproductive Endocrinology at the University of California, San Diego.